Ashley Rawls, MD
Neurology · Stanford, CANPI 1477968451
Payments from drug & device makers
What this record shows
This record is dominated by grants: $43,750 of the $48,066 with a category attached, or 91.0%. Medtronic accounts for 99.4% of it on its own, with 1 other manufacturer making up the rest. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $1172.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$48K
- Boston Scientific$290
What the payments were for
- Grants$43,75091%
- Travel & lodging$2,9256%
- Food & beverage$1,3223%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 38 | $47,776 |
| Boston Scientific | 3 | $290 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$44,475
- PERCEPT PC BRAINSENSE$2,126
- SPECTRA WAVEWRITER$223
How this compares
$48,066 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $97,452 |
| AustedoDeutetrabenazine | 11 | $45,696 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 167 | $6,472 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 73 | $4,959 |
| AmantadineAmantadine Hcl | 27 | $1,876 |
| Clozapine | 38 | $1,342 |
| Baclofen | 43 | $1,082 |
| Clonazepam | 43 | $830 |
| Atropine Sulfate | 16 | $786 |
| Gabapentin | 28 | $744 |
| Propranolol Hcl ErPropranolol Hcl | 27 | $721 |
| Primidone | 13 | $514 |
| Pregabalin | 21 | $427 |
| Ropinirole Hcl | 23 | $392 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 19 | $292 |
Paid to pharmacies, not to this prescriber.
Other neurology in Stanford
- Jeffrey DunnStanford$437K
- Neelam GoyalStanford$270K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.